Details

Autor(en) / Beteiligte

• Lobo Prabhu, Kristel C., M.D
• Vu, Lan, M.D., F.R.C.S.C
• Chan, Simon K., M.Sc
• Phang, Terry, M.D., F.R.C.S.C
• Gown, Allen, M.D
• Jones, Steven J., Ph.D
• Wiseman, Sam M., M.D., F.R.C.S.C

Titel

Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer

Ist Teil von

• The American journal of surgery, 2014-05, Vol.207 (5), p.712-716

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background Cyclo-oxygenase-2 (COX-2), an inducible enzyme expressed in areas of inflammation, is a target of interest for colorectal cancer therapy. Currently, the predictive significance of COX-2 in colorectal cancer remains unclear. Methods Tissue microarrays were constructed using 118 colon cancer and 85 rectal cancer specimens; 44 synchronous metastatic colon cancer and 22 rectal cancer lymph nodes were also evaluated. COX-2 expression was assessed by immunohistochemistry. Univariate analysis was used to determine the predictive significance of clinicopathologic variables. Overall survival, disease-specific survival, and disease-free survival were the main outcomes examined. Results COX-2 was found to be expressed in 93% of colon cancers and 87% of rectal cancers. Decreased COX-2 expression was related to decreased disease-specific survival ( P = .016) and decreased disease-free survival ( P = .019) in the rectal cancer cohort but not in the colon cancer cohort. Conclusions COX-2 expression has predictive utility for management of rectal but not colon cancer.